Sutro Biopharma (STRO) said late Thursday it appointed Jane Chung as its new chief executive and plans to nearly halve its workforce, following a strategic review of the company's portfolio.
Chung, who was chief operating officer of the company, will succeed Bill Newell as CEO, effective March 13. Newell will remain with Sutro in an advisory capacity.
Sutro said it aims to reduce its headcount by almost 50% with the layoffs to be substantially completed by the end of 2025. The restructuring is expected to cost the company between $40 million and $45 million.
As part of the review, the company will now focus on the development of its three wholly-owned preclinical programs in its cancer treatments pipeline, and deprioritize additional investment into the development of luvelta tazevibulin, its therapeutic candidate for certain types of ovarian cancer.
Sutro intends to continue exploring global out-licensing opportunities for luvelta.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。